Lancet: Study Suggests Cheap Asthma Drug Budesonide Effective At Reducing CV Recovery Times

A Texas doctor who started using and promoting this treatment to patients back in March 2020 was pilloried for it and censored on social media.

Quote :: In patients in the community with #COVID19 aged ≥65 years or ≥50 years with comorbidities, inhaled #budesonide reduced time to first self-reported recovery—an estimated 2.94 days sooner than usual care group, PRINCIPLE trial indicates.

Read: https://t.co/ir4Bn4dlW3 pic.twitter.com/3E66TI8SPI
— The Lancet (@TheLancet) August 11, 2021

From The Pharmaceutical Journal:

Quote :: Trial demonstrates efficacy of inhaled budesonide to treat COVID-19 in the community

Findings from the PRINCIPLE trial suggest that inhaled budesonide can improve recovery time and could reduce hospital admissions or death from COVID-19 if administered early.

By Julia Robinson | 11 August 2021

Inhaled budesonide should be considered for patients with COVID-19 who are at higher risk of complications in the community, according to results from a UK-wide clinical study.

The 'Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses' (PRINCIPLE) is the first randomised trial to demonstrate effectiveness of inhaled budesonide to treat COVID-19 in the community.

It builds on earlier evidence from the phase II 'Steroids in COVID-19' (STOIC) trial, which found that early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.

Anarcho-Capitalist Categorical Imperatives